

Remarks

By this amendment claims 22-24, 30-33 and 35 are amended in accordance with the Examiner's suggestions. Claims 22-24, 30-33 and 35 are pending. Support can be found in the specification as filed, in particular as found in the previous claim set and as described below. No issue of new matter arises.

Examiner Interview Summary

Applicants express their gratitude for the courtesies extended to their representative in scheduling and conducting the March 2, 2010 interview. The substance of the interview is incorporated in the following remarks.

Claim Objections

Claims 22-24, 30-33 and 35 were objected to with suggestions for obviating the rejections proposed by the Examiner. Claims 22-24, 30-33 and 35 as amended are believed to reflect these suggestions. Reconsideration and withdrawal of these objections are respectfully requested.

Rejections under 35 U.S.C. §112, second paragraph

Claims 22-24, 30, 32 and 33 were rejected under 35 U.S.C. §112, second paragraph. The claim set is amended above in accordance with the Examiner's suggestions. Reconsideration and withdrawal of this rejection are respectfully requested.

Conclusion

In view of the above amendments and remarks, Applicant respectfully requests reconsideration and withdrawal of all pending rejections. Applicant respectfully submits that the application is now in condition for allowance and request prompt issuance of a Notice of Allowance. Should the Examiner believe that anything further is desirable that might put the application in even better condition for allowance, the Examiner is requested to contact the undersigned at the telephone number listed below.

Fees

Any fees necessitated by the instant response are authorized for payment. Authorization is hereby given to charge Deposit Account no. 18-1982 for any underpayment, or to credit any overpayments.

Respectfully submitted,

/George S. Jones/
George S. Jones (Reg. No. 38,508)
Attorney for Applicant

sanofi-aventis US Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3776
Telefax (908) 231-2626
Sanofi-aventis Docket No.: DEAV2001/0008 US NP